Zhai X - Search Results

1

A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment.

Zhang J, Xu S, Yue L, Lei H, Zhai X. Zhang J, et al. Among authors: zhai x. J Med Chem. 2025 Jan 9;68(1):49-80. doi: 10.1021/acs.jmedchem.4c02809. Epub 2024 Dec 27. J Med Chem. 2025. PMID: 39726379 Review.

2

Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment.

Wei X, Yue L, Zhao B, Jiang N, Lei H, Zhai X. Wei X, et al. Among authors: zhai x. Eur J Med Chem. 2024 Nov 5;277:116785. doi: 10.1016/j.ejmech.2024.116785. Epub 2024 Aug 24. Eur J Med Chem. 2024. PMID: 39191032 Review.

3

Discovery of Novel 4,5,6,7-Tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one Derivatives as Orally Efficacious ATX Allosteric Inhibitors for the Treatment of Pulmonary Fibrosis.

Ma D, Tan Z, Li S, Zhao B, Yue L, Wei X, Xu S, Jiang N, Lei H, Zhai X. Ma D, et al. Among authors: zhai x. J Med Chem. 2025 Jan 9;68(1):792-818. doi: 10.1021/acs.jmedchem.4c02719. Epub 2024 Dec 25. J Med Chem. 2025. PMID: 39720950

4

Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.

Wang Y, Zhang G, Hu G, Bu Y, Lei H, Zuo D, Han M, Zhai X, Gong P. Wang Y, et al. Among authors: zhai x. Eur J Med Chem. 2016 Nov 10;123:80-89. doi: 10.1016/j.ejmech.2016.06.056. Epub 2016 Jul 12. Eur J Med Chem. 2016. PMID: 27474925

5

Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.

Jing T, Miao X, Jiang F, Guo M, Xing L, Zhang J, Zuo D, Lei H, Zhai X. Jing T, et al. Among authors: zhai x. Bioorg Med Chem. 2018 May 1;26(8):1784-1796. doi: 10.1016/j.bmc.2018.02.023. Epub 2018 Feb 21. Bioorg Med Chem. 2018. PMID: 29496411

6

Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties.

Lei H, Jiang N, Miao X, Xing L, Guo M, Liu Y, Xu H, Gong P, Zuo D, Zhai X. Lei H, et al. Among authors: zhai x. Eur J Med Chem. 2019 Jun 1;171:297-309. doi: 10.1016/j.ejmech.2019.03.038. Epub 2019 Mar 23. Eur J Med Chem. 2019. PMID: 30927566

7

An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects.

Lei H, Jia F, Cao M, Wang J, Guo M, Zhu M, Zuo D, Zhai X. Lei H, et al. Among authors: zhai x. Bioorg Med Chem. 2019 Oct 15;27(20):115051. doi: 10.1016/j.bmc.2019.115051. Epub 2019 Aug 21. Bioorg Med Chem. 2019. PMID: 31492532

8

Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.

Jiang N, Zhou Y, Zhu M, Zhang J, Cao M, Lei H, Guo M, Gong P, Su G, Zhai X. Jiang N, et al. Among authors: zhai x. Eur J Med Chem. 2020 Feb 1;187:111904. doi: 10.1016/j.ejmech.2019.111904. Epub 2019 Nov 19. Eur J Med Chem. 2020. PMID: 31806537

9

Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great In Vivo Efficacy in a Mouse Lung Fibrosis Model.

Lei H, Guo M, Li X, Jia F, Li C, Yang Y, Cao M, Jiang N, Ma E, Zhai X. Lei H, et al. Among authors: zhai x. J Med Chem. 2020 Jul 9;63(13):7326-7346. doi: 10.1021/acs.jmedchem.0c00506. Epub 2020 Jun 12. J Med Chem. 2020. PMID: 32479084

10

Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.

Lei H, Li C, Yang Y, Jia F, Guo M, Zhu M, Jiang N, Zhai X. Lei H, et al. Among authors: zhai x. Eur J Med Chem. 2020 Sep 1;201:112456. doi: 10.1016/j.ejmech.2020.112456. Epub 2020 Jun 1. Eur J Med Chem. 2020. PMID: 32535330

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,872 results

Search Page

Filters